» Articles » PMID: 35022275

Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis Through a TGF-β1-Induced OCT4/Nanog Pathway

Abstract

Hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection accelerates liver fibrosis progression compared with HBV or HCV monoinfection. Octamer binding transcription factor 4 (OCT4) and Nanog are direct targets of the profibrogenic TGF-β1 signaling cascade. We leveraged a coculture model to monitor the effects of HBV and HCV coinfection on fibrogenesis in both sodium taurocholate cotransporting polypeptide-transfected Huh7.5.1 hepatoma cells and LX2 hepatic stellate cells (HSCs). We used CRISPR-Cas9 to knock out OCT4 and Nanog to evaluate their effects on HBV-, HCV-, or TGF-β1-induced liver fibrogenesis. HBV/HCV coinfection and HBx, HBV preS2, HCV Core, and HCV NS2/3 overexpression increased TGF-β1 mRNA levels in sodium taurocholate cotransporting polypeptide-Huh7.5.1 cells compared with controls. HBV/HCV coinfection further enhanced profibrogenic gene expression relative to HBV or HCV monoinfection. Coculture of HBV and HCV monoinfected or HBV/HCV coinfected hepatocytes with LX2 cells significantly increased profibrotic gene expression and LX2 cell invasion and migration. OCT4 and Nanog guide RNA independently suppressed HBV-, HCV-, HBV/HCV-, and TGF-β1-induced α-SMA, TIMP-1, and Col1A1 expression and reduced Huh7.5.1, LX2, primary hepatocyte, and primary human HSC migratory capacity. OCT4/Nanog protein expression also correlated positively with fibrosis stage in liver biopsies from patients with chronic HBV or HCV infection. In conclusion, HBV and HCV independently and cooperatively promote liver fibrogenesis through a TGF-β1-induced OCT4/Nanog-dependent pathway.

Citing Articles

Integrative analysis of serum proteomics and transcriptomics in hepatitis C.

Wang J, Xia A, Tang M, Yang S, Shen Y, Dao J Virol J. 2025; 22(1):73.

PMID: 40082995 PMC: 11905632. DOI: 10.1186/s12985-025-02690-1.


The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.

Yuan H, Xu R, Li S, Zheng M, Tong Q, Xiang M MedComm (2020). 2025; 6(3):e70121.

PMID: 40060195 PMC: 11890166. DOI: 10.1002/mco2.70121.


In Vivo and In Vitro Models of Hepatic Fibrosis for Pharmacodynamic Evaluation and Pathology Exploration.

Hu Y, Zhang Z, Adiham A, Li H, Gu J, Gong P Int J Mol Sci. 2025; 26(2).

PMID: 39859410 PMC: 11766297. DOI: 10.3390/ijms26020696.


Antiviral Effects and Mechanisms of Active Ingredients in Tea.

Zhang X, Yu H, Sun P, Huang M, Li B Molecules. 2024; 29(21).

PMID: 39519859 PMC: 11547931. DOI: 10.3390/molecules29215218.


HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1α- and TGF-β1-dependent pathway.

Xu M, Warner C, Duan X, Cheng Z, Jeyarajan A, Li W J Hepatol. 2024; 80(6):868-881.

PMID: 38311121 PMC: 11102332. DOI: 10.1016/j.jhep.2024.01.026.


References
1.
Sakata K, Hara M, Terada T, Watanabe N, Takaya D, Yaguchi S . HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor. Sci Rep. 2013; 3:3243. PMC: 3837337. DOI: 10.1038/srep03243. View

2.
Lee L, Dai C, Chuang W, Chang W, Hou N, Hsieh M . Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol. 2007; 22(4):515-7. DOI: 10.1111/j.1440-1746.2006.04547.x. View

3.
Lin W, Weinberg E, Chung R . Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis. 2013; 207 Suppl 1:S13-8. PMC: 3611768. DOI: 10.1093/infdis/jis926. View

4.
Lin W, Wu G, Li S, Weinberg E, Kumthip K, Peng L . HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem. 2010; 286(4):2665-74. PMC: 3024762. DOI: 10.1074/jbc.M110.168286. View

5.
Ladner S, Otto M, Barker C, Zaifert K, Wang G, Guo J . Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997; 41(8):1715-20. PMC: 163991. DOI: 10.1128/AAC.41.8.1715. View